INVENTIVA S.A.(PROM.)-01
Research INVENTIVA S.A.(PROM.)-01 (6IV) on Bullrun: market cap EUR 683.86M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- Ticker6IV
- ExchangeF
- CountryFrance
- SectorHealthcare
- IndustryBiotechnology
- CurrencyEUR
- Market capEUR 683.86M
- Financial periodFY2025
- RevenueEUR 4.48M
- Revenue growth-51.3%
- Net income-EUR 354.14M
- Free cash flow-EUR 105.13M
Valuation Snapshot
latest market cap is EUR 683.86M.
About INVENTIVA S.A.(PROM.)-01
Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and other diseases in France and internationally. It develops Lanifibranor, a novel peroxisome proliferator-activated receptor agonist that is in the NATiV3 Phase 3 clinical trial to treat adult patients with MASH; and Odiparcil for the treatment of patients with mucopolysaccharidoses.
Frequently asked questions
What is INVENTIVA S.A.(PROM.)-01's market cap?
INVENTIVA S.A.(PROM.)-01's market capitalization is EUR 683.86M.
What does INVENTIVA S.A.(PROM.)-01 do?
Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and other diseases in France and internationally.